Saudi hospital cuts CAR-T cost 80% with in-house manufacturing

By AI, Created 11:41 AM UTC, May 20, 2026, /AGP/ – King Faisal Specialist Hospital and Research Centre says it has reduced CAR-T treatment costs from about SAR 1.3 million to SAR 250,000 per case while cutting manufacturing time in half. The move adds a real-world data point to the global push to make advanced cell therapies faster and more affordable.

Why it matters: - KFSH’s cost reduction could make CAR-T therapy more accessible for patients and payers facing six-figure treatment bills. - The faster turnaround also matters clinically for aggressive blood cancers, where delays can affect eligibility and outcomes. - The hospital’s model adds evidence that point-of-care cell manufacturing may lower the economics of advanced therapies without sacrificing quality.

What happened: - King Faisal Specialist Hospital and Research Centre reduced CAR-T treatment costs from about SAR 1.3 million, or roughly $347,000, per case to around SAR 250,000, or about $67,000. - KFSH cut manufacturing time from about 28 days to under 14 days. - The hospital has treated more than 200 CAR-T patients since 2020. - In March 2025, KFSH gave its first dose of an in-house manufactured CD19-directed CAR-T therapy to a patient in a Phase I clinical trial for relapsed or refractory B-cell acute lymphoblastic leukemia. - The program moved from an international manufacturing pathway to hospital-based production.

The details: - The earlier model required shipping patient cells abroad and returning the engineered product under strict cold-chain conditions. - KFSH adopted a closed, automated production system inside the hospital. - Miltenyi Biotec developed the system in collaboration with KFSH. - The Saudi Food and Drug Authority oversaw the process. - CAR-T therapies approved in the United States are typically priced between about $450,000 and $500,000 per infusion before supportive care. - Those prices have strained commercial and public payers and limited referrals at many cancer centers. - KFSH’s lower manufacturing time gives clinicians more flexibility for patients with fast-moving disease.

Between the lines: - The KFSH data points to a possible path for hospitals that want to bring advanced cell therapy production closer to the patient. - The key question is whether this cost structure can be replicated outside Saudi Arabia. - The United States would face different regulatory, labor, and reimbursement hurdles. - The hospital’s results arrive as global scrutiny over cancer treatment costs intensifies.

What’s next: - KFSH will present as a Silver Sponsor at the Milken Institute Global Conference 2026 in Los Angeles from May 3 to 6. - The conference will gather leaders from healthcare, finance, technology and public policy to discuss the future of global health systems. - Researchers and health systems will likely watch whether other markets can adapt the hospital-based manufacturing model. - More data from active clinical programs will help test whether point-of-care production can scale.

The bottom line: - KFSH has turned CAR-T manufacturing into a faster, cheaper hospital-based process, offering one of the clearest operational examples yet of how advanced cancer therapy costs might come down.